Filing Details

Accession Number:
0000899243-18-019862
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-13 20:00:30
Reporting Period:
2018-07-12
Accepted Time:
2018-07-13 20:00:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1285819 Omeros Corp OMER Pharmaceutical Preparations (2834) 911663741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472163 S. Marcia Kelbon 201 Elliott Avenue West
Seattle WA 98119
Vp Patent And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-12 4,277 $4.10 188,922 No 4 M Direct
Common Stock Disposition 2018-07-12 4,277 $21.48 184,645 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-07-12 4,277 $0.00 4,277 $4.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
83,252 2022-01-07 No 4 M Direct
Footnotes
  1. Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2017, and amended on May 17, 2018. The trading schedule, including sale periods, price and the number of shares to be sold, was established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. This transaction was executed in multiple trades at prices ranging from $21.46 to $21.49; the price reported above reflects the weighted average sales price. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  3. The option vested and became exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2011.